This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
KANSAS CITY, Kan. and
Nov. 11, 2013 /PRNewswire/ --
Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has appointed
Craig Tooman to the position of Chief Financial Officer and named
John C. Ayres as its General Counsel. Louise Mawhinney, former CFO of Aratana, will remain with the company.
Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics stated, "Aratana has grown considerably over the past year, having successfully completed our initial public offering in June and now, with the acquisition of Vet Therapeutics, becoming a commercial company. The appointments of
Craig Tooman and
John Ayres, both highly experienced commercial biopharmaceutical executives, will substantially enhance our strategy to establish Aratana as the industry leader in pet therapeutics. I'm extremely pleased to welcome Craig and John to our executive team and look forward to benefitting from their depth of knowledge and strategic vision."
A seasoned pharmaceutical executive with more than 20 years of industry experience, Mr. Tooman is widely versed in international finance, sales, market research, business intelligence, corporate strategy, M&A and investor relations. Immediately prior to his joining the executive team, Mr. Tooman had served as a Director and Chairman of Aratana's Audit Committee; he served as a member of the Board of Directors from
March 2012 until his appointment as Chief Financial Officer. Mr. Tooman will also transition from his current position of CEO of Avanzar Medical, Inc., an oncology company, to focus on Aratana.
Previously, Mr. Tooman held executive positions at large pharmaceutical companies, including Pharmacia and Upjohn, and served as the CFO of Enzon Pharmaceuticals and Ikaria. While at ILEX Oncology, Mr. Tooman was a member of the executive team and was instrumental in transitioning the company from a CRO into a proprietary business responsible for developing successful oncology products. This strategic transformation ultimately led to ILEX being sold to Genzyme Corporation for
Mr. Ayres joins Aratana from Amgen Inc. where he served as a member of the Corporate and Securities Law group for the world's largest independent biotechnology company. Within Amgen, Mr. Ayres advised the company's finance, human resources, investor relations and corporate communications groups. Prior to Amgen, Mr. Ayres was an associate at Latham & Watkins LLP where he specialized in public company counsel, including SEC compliance, initial public and follow-on stock offerings and mergers and acquisitions.